SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-014105 to MeiraGTx Holdings plc (MGTX) (CIK 0001735438) (MGTX)

MeiraGTx Holdings plc (MGTX) (CIK 0001735438)
Date: Dec. 27, 2023 · CIK: 0001735438 · Accession: 0000000000-23-014105

AI Filing Summary & Sentiment

File numbers found in text: 333-276183

Date
December 27, 2023
Author
Not clearly detected
Form
UPLOAD
Company
MeiraGTx Holdings plc (MGTX) (CIK 0001735438)

Letter

United States securities and exchange commission logo December 27, 2023 Robert Wollin General Counsel MeiraGTx Holdings plc 450 East 29th Street, 14th Floor New York, New York 10016 Re:MeiraGTx Holdings plc Registration Statement on Form S-3 Filed December 21, 2023 File No. 333-276183 Dear Robert Wollin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter Handrinos

Show Raw Text
United States securities and exchange commission logo
December 27, 2023
Robert Wollin
General Counsel
MeiraGTx Holdings plc
450 East 29th Street, 14th Floor
New York, New York 10016
Re:MeiraGTx Holdings plc
Registration Statement on Form S-3
Filed December 21, 2023
File No. 333-276183
Dear Robert Wollin:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Peter Handrinos